Verheggen Raphaela, Werner Inga, Lücker Anne, Brüss Michael, Göthert Manfred, Kaumann Alberto J
Department of Neurosurgery, University of Göttingen, Göttingen, Germany.
Pharmacogenet Genomics. 2006 Aug;16(8):601-7. doi: 10.1097/01.fpc.0000220564.52348.63.
Expression studies of the rare Phe124Cys sequence variant of the human 5-HT1B receptor in HEK293 cells demonstrated that 5-hydroxytryptamine (5-HT) and sumatriptan had both three times higher binding affinity and agonist potency at the variant receptor than wild-type receptor. We examined whether in-vivo expression of the variant compared to the wild-type Phe/Phe genotype at codon 124 of the 5-HT1B receptor in human temporal arteries modifies their agonist-induced contraction.
Rings of arteries, coexpressing 5-HT1B and 5-HT2A receptors, from 98 patients undergoing neurosurgery were set up to measure contraction. Blood sample genotyping was performed by PCR using a mutagenic primer which induces a NheI restriction site in the Cys but not in the Phe allele.
Three patients exhibited the Cys/Phe genotype, probably yielding coexpression of both the 124Phe and the 124Cys 5-HT1B receptors. In 95 Phe/Phe patients, exclusively the 124Phe receptor was expressed. The contractile potencies of 5-HT and sumatriptan were not significantly different in arteries from Cys/Phe or Phe/Phe individuals. The 5-HT1B receptor-selective antagonist SB224289 was five-fold more potent in blocking the effects of 5-HT in arteries from three Cys/Phe than from 30 Phe/Phe individuals (P < 0.03). The fraction of 5-HT effects via 5-HT1B receptors, related to the total contractile amplitude via 5-HT1B and 5-HT2A receptors, was enhanced from 0.42 +/- 0.03 in 88 Phe/Phe individuals to 0.75 +/- 0.10 in three Cys/Phe individuals (P < 0.05).
Although the potency of 5-HT1B receptor agonists does not differ between arteries from Phe/Phe and Cys/Phe individuals, the contribution of 5-HT1B receptors to the mediation of the effects of 5-HT is increased in Cys/Phe individuals.
在HEK293细胞中对人5-HT1B受体罕见的Phe124Cys序列变体进行表达研究,结果表明5-羟色胺(5-HT)和舒马曲坦与该变体受体的结合亲和力和激动剂效力均比野生型受体高三倍。我们研究了在人颞动脉中,5-HT1B受体第124位密码子处变体与野生型Phe/Phe基因型相比,其体内表达是否会改变激动剂诱导的收缩。
从98例接受神经外科手术的患者获取共表达5-HT1B和5-HT2A受体的动脉环,用于测量收缩情况。采用诱变引物通过PCR进行血样基因分型,该引物可在Cys等位基因而非Phe等位基因中诱导NheI限制性位点。
3例患者表现为Cys/Phe基因型,可能同时表达124Phe和124Cys两种5-HT1B受体。在95例Phe/Phe患者中,仅表达124Phe受体。Cys/Phe或Phe/Phe个体动脉中5-HT和舒马曲坦的收缩效力无显著差异。5-HT1B受体选择性拮抗剂SB224289在阻断3例Cys/Phe个体动脉中5-HT的作用方面,效力比阻断30例Phe/Phe个体动脉中5-HT的作用高五倍(P < 0.03)。5-HT通过5-HT1B受体产生的效应占5-HT1B和5-HT2A受体介导的总收缩幅度的比例,从88例Phe/Phe个体中的0.42±0.03增加到3例Cys/Phe个体中的0.75±0.10(P < 0.05)。
尽管Phe/Phe和Cys/Phe个体动脉中5-HT激动剂的效力无差异,但在Cys/Phe个体中,5-HT1B受体对5-HT效应介导的贡献增加。